Efficacy prediction and molecular mechanism of thyroid hormone levels and multi-target TKI therapy for renal cell carcinoma and hepatocellular carcinoma
10.3760/cma.j.issn.1673-422X.2019.05.011
- VernacularTitle:甲状腺激素水平与肾细胞癌及肝细胞癌多靶点TKI治疗疗效预测及其分子机制
- Author:
Yueqin SUN
1
;
Aimin LI
;
Yue LUO
;
Zhenghui SONG
;
Xuefen ZHUANG
;
Guanqi DAI
;
Xinhui LIU
Author Information
1. 南方医科大学中西医结合医院肝胆胰肿瘤科
- Keywords:
Thyroid hormones;
Neoplasms;
Prognosis;
Tyrosine kinase inhibitors
- From:
Journal of International Oncology
2019;46(5):303-306
- CountryChina
- Language:Chinese
-
Abstract:
Hypothyroidism is a common adverse reaction in clinical multi-target tyrosine kinase inhibitor (TKI) and may be used as a predictor of efficacy of TKI drugs.Studies show that hypothyroidism is significantly associated with good prognosis in patients with renal cell carcinoma treated with multi-target TKI,which may be related to inhibition of vascular endothelial growth factor receptor pathway,potential off-target effects and inhibition of cell proliferation.Whereas in the patients with hepatocellular carcinoma who received multi-target TKI therapy,hypothyroidism is an indicator of poor prognosis,which is related to the T3/TR pathway regulating liver cancer growth and invasion.The predictive function and mechanism of thyroid hormone levels in different tumor patients receiving multi-target TKI drugs are different,and further research is still needed.
